Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia-Reference-Cited by-同舟云学术

Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

Published:2021-11 Issue:11 Volume:2 Page:1204-1223
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Bosc Claudie^ORCID,Saland Estelle,Bousard Aurélie,Gadaud Noémie,Sabatier Marie,Cognet Guillaume^ORCID,Farge Thomas,Boet Emeline,Gotanègre Mathilde,Aroua Nesrine,Mouchel Pierre-Luc^ORCID,Polley Nathaniel,Larrue Clément,Kaphan Eléonore,Picard Muriel,Sahal Ambrine,Jarrou Latifa,Tosolini Marie^ORCID,Rambow Florian,Cabon Florence,Nicot Nathalie,Poillet-Perez Laura,Wang Yujue,Su Xiaoyang,Fovez Quentin^ORCID,Kluza Jérôme,Argüello Rafael José^ORCID,Mazzotti Céline,Avet-Loiseau Hervé,Vergez François,Tamburini Jérôme,Fournié Jean-Jacques,Tiong Ing S.^ORCID,Wei Andrew H.^ORCID,Kaoma Tony,Marine Jean-Christophe,Récher Christian^ORCID,Stuani Lucille^ORCID,Joffre Carine^ORCID,Sarry Jean-Emmanuel^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s43018-021-00264-y.pdf

Reference89 articles.

1. Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104–108 (2017).

2. Short, N. J. et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 10, 506–525 (2020).

3. Intlekofer, A. M. et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature 559, 125–129 (2018).

4. McMahon, C. M. et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-1453 (2019).

5. Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716–735 (2017).

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma;Journal of Experimental Medicine;2024-09-05

2. CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator;Cell Death & Disease;2024-08-27

3. Mitohormesis : la clé de voûte de la résistance thérapeutique des cellules cancéreuses;Comptes Rendus. Biologies;2024-08-22

4. YY1 downregulation underlies therapeutic response to molecular targeted agents;2024-08-06

5. Metabolic profiling of glioblastoma stem cells reveals pyruvate carboxylase as a critical survival factor and potential therapeutic target;Neuro-Oncology;2024-06-13